JW Asset Management’s Travere Therapeutics TVTX Stock Holding History

JW Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.7M	Buy	+30,000	New	+$1.33M	0.53%	13
2015 Q4	–	Sell	-24,147	Closed	-$489K	–	50
2015 Q3	$489K	Buy	24,147 +223	+0.9%	+$6.61K	0.18%	39
2015 Q2	$793K	Buy	23,924 +6,478	+37%	+$177K	0.24%	38
2015 Q1	$418K	Buy	17,446 +987	+6%	+$15.1K	0.18%	38
2014 Q4	$202K	Buy	+16,459	New	+$170K	0.15%	36

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JW Asset Management's TVTX Position: Q2 2026 in Review

JW Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 30,000 shares worth $1.7M. The stake represents 0.53% of the portfolio and ranks #13 among its holdings. This is a return to the name: JW Asset Management previously reported a position in TVTX as recently as Q3 2015.

JW Asset Management first reported a position in TVTX in Q4 2014 and has held it in 5 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

JW Asset Management held 30,000 shares of Travere Therapeutics worth $1.7M as of Q2 2026.
Travere Therapeutics was a new JW Asset Management position in Q2 2026.
Travere Therapeutics made up 0.53% of JW Asset Management's portfolio in Q2 2026, its #13 holding.
JW Asset Management first reported a position in Travere Therapeutics in Q4 2014 and has held it in 5 quarters since.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on JW Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.